NexImmune is an early stage biopharmaceutical company developing novel immuno-therapeutics based on the proprietary Artificial IMmune (AIM„¢) nanotechnology platform. Central to the AIM„¢ technology are artificial Antigen Presenting Cells (aAPC) that can be engineered to orchestrate a highly targeted immune attack directed toward specific foreign substances or cell types in the body. In preclinical studies, aAPCs have demonstrated potential utility as vaccines and therapeutic agents and can also be used for the development of diagnostic products. NexImmune is using the AIM technology platform to develop a pipeline of products to treat cancer.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/21/14 | $3,000,000 |
Amgen Business Development Pfizer Venture Investments | undisclosed |
